[Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Chronic heart failure with preserved left ventricular ejection fraction (HFpEF) lacks effective treatments to improve patient prognosis.
• Current therapeutic strategies for HFpEF are largely empirical.

Purpose of the Study:

• To compare the long-term effectiveness of ivabradine versus bisoprolol in patients with HFpEF.
• To evaluate the impact of these treatments on clinical status, exercise tolerance, quality of life, and cardiac function.

Main Methods:

• A prospective randomized study involving 126 patients with HFpEF (left ventricular ejection fraction ≥ 50%).
• Patients were treated with either bisoprolol (n=62) or ivabradine (n=64) for 12 months.
• Assessments included clinical status, exercise tolerance, quality of life, N-terminal brain natriuretic peptide precursor levels, and echocardiography.

Main Results:

• Ivabradine significantly improved exercise tolerance and quality of life compared to bisoprolol.
• Ivabradine led to a significant reduction in N-terminal brain natriuretic peptide precursor levels.
• Improvements in left ventricular diastolic function, including active relaxation and compliance, were observed with ivabradine.

Conclusions:

• Ivabradine demonstrates superior efficacy over bisoprolol in improving functional capacity and quality of life for HFpEF patients.
• Ivabradine positively impacts cardiac remodeling and reduces cardiac stress markers in HFpEF.
• Ivabradine represents a promising therapeutic option for managing heart failure with preserved ejection fraction and left ventricle diastolic dysfunction.